Shares of McKesson (NYSE: MCK ), a health services company and pharmaceutical distributor, climbed Tuesday, surging by the most in over three years after it reported earnings and guidance that topped consensus.
Revenue for its fiscal fourth quarter climbed 4% to $68.9 billion and adjusted EPS was up 23% to $7.19. Both beat consensus estimates. It also issued 2024 guidance that beat Wall Street expectations, indicating strong growth. Additionally, McKesson lifted long-term targets for its U.S. Pharmaceutical, Prescription Technology Solutions and Medical-Surgical Solutions business segments.
At least seven banks raised their price target on the stock Tuesday morning. Leading the pack was research firm TD Cowen. It raised its price target on McKesson from $416 to a Street-high $491. Analysts were impressed by the company’s guidance, calling it “much better than expected.”
“We remain positive on MCK as FY24 guide $26.10-26.90 came in much better than expected, with midpoint $26.50 well above cons $25.90 and our $25.04, driven by expected growth in US Pharma and RxTS, and expected $3.5B share repo. Ex one-time FY23 items (incl COVID), midpoint implies FY24 adj EPS +11%-14%. In addition, MCK increased its LT growth targets indicating fundamentals continue to be strong,” said TD Cowen analysts.
Morgan Stanley analysts also weighed in on results, saying, “While MCK's F4Q print was operationally lower than expected, its 2024 guidance and increased long term profit targets should drive greater enthusiasm for the shares tomorrow on the additional clarity.”
Shares of McKesson climbed by as much as 8.5% before paring gains to around 6.5%.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.